Cite
HARVARD Citation
Gattorno, M. et al. (2017). Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Annals of the rheumatic diseases. 76 (1), pp. 173-178. [Online].